New Breast Cancer Drug (Perjeta) Boosts Survival When Added To The Current Gold Stand
 

New survival data from the Phase III CLEOPATRA study, revealed at the San Antonio Breast Cancer Symposium (SABCS), demonstrate that Perjeta reduces the risk of death by 34% in patients with previously untreated advanced HER2-positive breast cancer, compared with the current gold standard of care - Herceptin and chemotherapy (docetaxel) (HR= 0.66; 95% CI 0.52-0.84)...

More...